加州大学旧金山分校Moslehi教授肿瘤心脏学团队诚招博后

1课题组介绍

Javid Moslehi教授在加州大学旧金山分校领导肿瘤心脏学、免疫学和新陈代谢交叉研究的新部门。该团队在Cancer Discovery, Nature Medicine, Cell, Circulation, N Engl J Med, Lancet 等学术期刊发表过一系列具有国际影响力的原创工作。现因实验室发展需要，招聘多名博士后，从事癌症免疫治疗相关的心血管毒性以及心脏病发病机制科学研究。分子或细胞生物学，遗传学，心脏学，肿瘤学，免疫学及相关学术背景均可申请，有动物模型和单细胞经验者优先考虑，感兴趣者可直接发邮件与Moslehi教授联系，也欢迎添加实验室成员微信进一步了解情况，联系方式见文末。

2Prof. Javid J. Moslehi, MD

• William Grossman Distinguished Professor in Cardiology
• Section Chief, Cardio-Oncology, Immunology and Metabolism
• Associate Professor in Residence
• UCSF School of Medicine, Cardiovascular Research Institute (CVRI)
• https://medicine.vumc.org/person/javid-j-moslehi-md
  (Current institute at Vanderbilt)

3Research Keywords

Cardio-Oncology,  Immunotherapy,  Myocarditis,  Cardiomyopathy, pre-clinical models, mouse models, Single nuclei/cell RNA sequencing, Bioinformatics, Pathogenesis

4Research Description

Prof. Moslehi has accepted a new position at University of California, San Francisco (UCSF) this October 2021. He will direct a new section of cardio-oncology, immunology, and metabolism at UCSF.

We are seeking a highly motivated candidate to be a Post-Doctoral Fellow in the Division of Cardiovascular Medicine and the Cardio-Oncology Program. The successful applicant will hold a Ph.D. and/or M.D. with experience in molecular biology, biochemistry and animal models. Ability to work independently and cooperatively within a team of clinicians and scientists is essential. This position is specifically tailored to an applicant with a strong immunology background. The Moslehi laboratory has an interest in fundamental interactions between the immune and cardiovascular systems. This interest has been partly motivated by the laboratory’s previous work in identifying clinical syndromes of immune-checkpoint inhibitor (ICI)-associated cardiovascular toxicities which include myocarditis, pericarditis and vasculitis (NEJM, 2016. Lancet, 2018. Lancet Oncology, 2018. Nature Medicine 2019, Circulation, 2020，Lancet Oncol 2021，Cancer Discovery, 2021). We have created pre-clinical models for ICI-associated myocarditis including pharmacologically-treated and genetic mouse models. The preliminary data from the laboratory suggest a critical role of immune checkpoint (specifically PD-1 and PD-L1) in the cardiac homeostasis and human cardiovascular disease, a hypothesis that is currently being tested in the laboratory.

Salary is dependent upon the applicant’s experience and follows NIH guidelines.

5Requirements

• PhD in genetics, molecular biology, cell biology, immunology, or related field.
• Skills in molecular biology techniques including single cell RNA sequencing, data analysis
• Enthusiastic, self-motivated, and able to actively lead complex translational projects.
• Excellent written and oral communication skills.

6To apply

• Please forward CV to Prof. Javid Moslehi at: [e-mail], Contact information for 3 references

• If you’d like to know more information, please don’t hesitate to contact Dr. Qin in Moslehi lab at Wechat:qjuane

7Please find our publications on Pubmed

https://pubmed.ncbi.nlm.nih.gov/?term=Javid+moslehi

Selected publications by our team:

1. Amancherla K...Moslehi J. RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets. Circulation Research. 2021. PMID: 34126013. https://pubmed.ncbi.nlm.nih.gov/34126013/
2. Wei SC, Meijers WC...Moslehi JJ*, Allison JP*. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discovery. 2021. PMID: 33257470 (*Co-Senior). https://pubmed.ncbi.nlm.nih.gov/33 257470/
3. Johnson DB...Salem JE...Moslehi JJ...Balko JM. Nat Med. 2019. PMID: 31332390. https://pubmed.ncbi.nlm.nih.gov/31332390/
4. Moslehi J, Salem JE...Johnson DB. Lancet. 2018. PMID: 2953652. https://pubmed.ncbi.nlm.nih.gov/29536852/
5. Johnson DB...Moslehi JJ. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016. PMID: 27806233. https://pubmed.ncbi.nlm.nih.gov/27806233/
6. Moslehi J. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med. 2016. PMID: 27732808. https://pubmed.ncbi.nlm.nih.gov/27732808/
7. Olenchock BA*, Moslehi J*...Kaelin WG Jr. Inhibition of the EgIN1 oxygen sensor and rerouting of a- ketoglutarate are sufficient for remote ischemic protection. Cell. 2016. PMID: 26919427 (*Co-First). https://pubmed.ncbi.nlm.nih.gov/26919427/

往期回顾

---

---

---

如果你对单细胞转录组研究感兴趣，但又不知道如何入门，也许你可以关注一下下面的课程

看完记得顺手点个“在看”哦！

生物 | 单细胞 | 转录组丨资料每天都精彩

长按扫码可关注